Rapport Therapeutics initiated with a Buy at Truist

Truist analyst Joon Lee initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $44 price target Rapport is focused on the central nervous system with a lead program in focal onset epilepsy, a therapeutic area worth $10B annually and growing, the analyst tells investors in a research note. The firm believes RAP-219’s magnitude and speed of seizure reduction is “impressive” and models over$1B in peak sales in 2038 for focal onset epilepsy alone.